![Quiver Logo](/static/img/logo-icon.png)
![ILMN logo](https://quiver-logos.s3.us-east-2.amazonaws.com/ilmn.png)
Illumina Inc
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2023 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view ILMN Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
$ILMN is featured in our Sector Weighted DC Insider and Transportation and Infra. Committee (House) strategies.
See All StrategiesRecent trades of ILMN by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by ILMN's directors and management
Government lobbying spending instances
New patents grants
Federal grants, loans, and purchases
Recent insights relating to ILMN
Recent picks made for ILMN stock on CNBC
ETFs with the largest estimated holdings in ILMN
Flights by private jets registered to ILMN
![Quiver Logo](/static/img/logo-icon.png)